PepGen is a clinical-stage biotechnology company developing next-generation of oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. It develops the Enhanced Delivery Oligonucleotide (EDO) platform. The EDO peptides are engineered to optimize tissue penetration, cellular update, and nuclear delivery.